Skip to main content
NewslettersWatchlist

Heron Therapeutics(HRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.30
Day High3.41
Open:3.40
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
AllPennyStocks.com
Biotech Finds Mid-Week Success Following Q4 Earnings Release
AllPennyStocks.com
Premarket Heats Up For Biotech Before Opening Bell
AllPennyStocks.com
Biotech Shares Up Sharply Following Quarterly Results
PR Newswire
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
PR Newswire
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
PR Newswire
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
PR Newswire
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
PR Newswire
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
PR Newswire
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
PR Newswire
Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
PR Newswire
Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference
Motley Fool
Why Heron Therapeutics Stock Has Been on Fire This Week
Motley Fool
Why Shares of Heron Therapeutics Jumped Thursday
Barchart
S&P Futures Plunge As Banking Sector Concerns Weigh On Sentiment
PR Newswire
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
PR Newswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023
PR Newswire
Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults
PR Newswire
Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference
PR Newswire
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
PR Newswire
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF
PR Newswire
Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference
PR Newswire
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
PR Newswire
Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
PR Newswire
Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)
Motley Fool
3 Stocks Expecting Good News From the FDA
PR Newswire
Heron Therapeutics Announces $76.5 Million Private Placement Financing
PR Newswire
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
PR Newswire
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability
PR Newswire
Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty
Motley Fool
Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.
Motley Fool
Why Heron Therapeutics Stock Is Getting Hammered Today

Profile

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.